Delving into the Latest Updates on Pharmbiotec GmbH with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

17β-HSD1(雌二醇17β-脱氢酶-1)	1

关联

1

项与 Pharmbiotec GmbH 相关的药物

17β-HSD1 inhibitor(Saarland University)

靶点

17β-HSD1

作用机制

17β-HSD1抑制剂

在研机构

Universität des Saarlandes [+2]

原研机构

Universität des Saarlandes

在研适应症

乳腺癌

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Pharmbiotec GmbH 相关的临床结果

登录后查看更多信息

0 项与 Pharmbiotec GmbH 相关的专利（医药）

登录后查看更多信息

24

项与 Pharmbiotec GmbH 相关的文献（医药）

2024-04-01·International Journal of Pharmaceutics

Biorelevant subcutaneous in vitro test predicts the release of human and fast acting insulin formulations

Article

作者: Mundinger, Patricia ; Knoth, Katharina ; Schöner, Tim A ; Lehr, Claus-Michael ; Louit, Guillaume ; Terán, Iria Torres ; Hittinger, Marius ; Vogel, Verena ; Venczel, Marta ; Marker, Alexander ; Kamm, Walter ; Paehler, Tobias ; Loos, Petra

The administration of insulins by subcutaneous injection is nowadays widely prevalent. The injection site is located below the dermis and composed of cells and the extracellular matrix formed of a network of macromolecules such as hyaluronic acid and collagen. Following an injection, the insulins from the formulated products are timely released as drug molecules from the injection site into systemic circulation. In this publication, we show the development of an in vitro setup utilizing a hydrogel composed of a special collagen-hyaluronic acid mixture that mimics the extracellular matrix. Another setup was used for differentiation of the commercially available and research insulin formulations by determining the in vitro permeation characteristics with the results that were correlated with the human in vivo data. Significant differentiation was achieved at 90 % confidence level between the permeation curves of insulin glulisine containing formulations (U100 and a concentrated research formulation), while in case of the insulin lispro containing formulations (U100 and U200) the permeation curves showed similarity. These results demonstrated that the in vitro setup may be used as a tool for formulation development and drug candidate profiling as it is able to differentiate or show similarities between the agglomeration states and concentration of the active pharmaceutical ingredients.

2022-04-01·Advanced Drug Delivery Reviews1区 · 医学

Models using native tracheobronchial mucus in the context of pulmonary drug delivery research: Composition, structure and barrier properties

1区 · 医学

Review

作者: Lehr, Claus-Michael ; Huck, Benedikt C ; Hidalgo, Alberto ; Murgia, Xabier ; Loretz, Brigitta ; Hittinger, Marius ; Frisch, Sarah

Mucus covers all wet epithelia and acts as a protective barrier. In the airways of the lungs, the viscoelastic mucus meshwork entraps and clears inhaled materials and efficiently removes them by mucociliary escalation. In addition to physical and chemical interaction mechanisms, the role of macromolecular glycoproteins (mucins) and antimicrobial constituents in innate immune defense are receiving increasing attention. Collectively, mucus displays a major barrier for inhaled aerosols, also including therapeutics. This review discusses the origin and composition of tracheobronchial mucus in relation to its (barrier) function, as well as some pathophysiological changes in the context of pulmonary diseases. Mucus models that contemplate key features such as elastic-dominant rheology, composition, filtering mechanisms and microbial interactions are critically reviewed in the context of health and disease considering different collection methods of native human pulmonary mucus. Finally, the prerequisites towards a standardization of mucus models in a regulatory context and their role in drug delivery research are addressed.

2021-10-10·Cureus

Systemic Curcumin-Human Serum Albumin in Proliferative Vitreoretinal Retinopathy: A Pilot Study

Article

作者: Schulz, Andre ; Al-Nawaiseh, Sami ; Bisorca-Gassendorf, Lukas ; Waizel, Maria ; Bohrer, Bianca ; Wakili, Phillip ; Rickmann, Annekatrin ; Januschowski, Kai

Objectives The purpose of this study is to compare the risks of novel postoperative curcumin infusion in patients with increased proliferative vitreoretinal retinopathy (PVR) after retinal detachment with steroid infusion or no treatment. Methods This was a prospective, non-randomized pilot study of 15 eyes of 15 patients (mean age 68 ± 7 years) with retinal detachment, macula off, and flare >15 pc/ms. Postoperatively, the patients received either curcumin-HSA (human serum albumin) infusion (C, n=5), prednisolone infusion (P, n=5), or no therapy (N, n=5) for three days. The outcome measures included postoperative PVR rate, the number of vitreoretinal surgeries (VRS) required, epiretinal membrane development, and visual acuity (VA). Results All patients had a preoperative VA of hand movements, macula-off detachment situation, and two quadrants rhegmatogenous retinal detachment. Patients underwent VRS at a mean time of 5.6 ± 1.5 (C), 4.9 ± 2.0 (P), 4.7 ± 1.2 (N) days after first recognized symptoms. Postoperative PVR developed just in one eye (P) after 16 days and required VRS due to PVR retinal detachment. The remaining 14 patients of group C and N did not develop PVR. BCVA improved six months post surgery to 0.56 ± 0.31 (P), 0.53 ± 0.19 (D), 0.53 ± 0.17 (N) logMAR. There were no side effects nor complications related to the postoperative infusions. Conclusions In this pilot study, we demonstrated that a postoperative application of curcumin infusion is a safe option in patients with an increased risk of PVR. Whether or not PVR can be reduced by curcumin infusion would require to be investigated in larger, randomized clinical trials.

100 项与 Pharmbiotec GmbH 相关的药物交易

登录后查看更多信息

100 项与 Pharmbiotec GmbH 相关的转化医学

登录后查看更多信息